RxDoctor Payments Data

Sarmad Said, MD

Cardiovascular Disease · Tulare, CANPI 1912266511

Payments from drug & device makers

$4,026in general payments, 2019–2025

Across 121 payments — averaging $33.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Johnson & Johnson$227
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$209
  • Abbott$160
  • Edwards Lifesciences$159
  • Atricure, Inc.$125
  • plus $471 from 12 others

What the payments were for

  • Food & beverage$4,026100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,026 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$708,334
Medicare patients
1,892
Services billed
7,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban324$437,826
EntrestoSacubitril/Valsartan244$376,653
EliquisApixaban271$375,412
ArcalystRilonacept12$276,659
JardianceEmpagliflozin114$158,308
BrilintaTicagrelor84$88,974
Repatha SureclickEvolocumab40$30,221
VerquvoVericiguat11$13,352
Ranolazine ErRanolazine145$13,239
Metoprolol Succinate521$7,693
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide208$6,600
Isosorbide Dinitrate103$5,963
Diltiazem 12hr ErDiltiazem Hcl14$5,191
Valsartan175$5,181
ClopidogrelClopidogrel Bisulfate369$4,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$227$437,826324 claims
NovartisEntresto$107$376,653244 claims
PfizerEliquis$13$375,412271 claims
Boehringer IngelheimJardiance$21$158,308114 claims
AstraZenecaBrilinta$38$88,97484 claims
MerckVerquvo$19$13,35211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Tulare

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →